Life-Sciences-Europe.com
The European Life Sciences Web Portal

This is a free web portal for the life sciences in Europe and Israel... » read more

Genentech Acquires CDK Inhibitors from Regor: $850m Upfront (2024-09-30)
Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones Cambridge, M...
Sequentia Biotech Raises €10m Series A Led by Seventure (2024-09-27)
Sequentia Biotech, a deeptech and leading bioinformatics company focused on the a108445nalysis and application of omics data, announces a €10million Series A, led by Seventure Partners, a French Venture Capital & Growth investment company with an extensive experi...
Evotec & Novo Nordisk: Cell Therapy Tech Development (2024-09-26)
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced to...
Genespire Srl: €46.6m Series B Led by Sofinnova, Xgen & CDP (2024-09-25)
> One of the largest private Italian Biotech company financings to date > Financing co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital forming a strong syndicate with Indaco SGR > Funds dedicated to advancing off-the-shelf pediatric gene thera...
Andreas Eckert on the IPO of Pentixapharm at FSE – Interview (2024-09-24)
First German Life Sciences IPO since 2016 – Radiopharma Company Pentixapharm Lists at Frankfurt Stock Exchange A dewy interview by |transkript.de/Georg Kääb with Andreas Eckert, Chair of Pentixapharm and major shareholder of Eckert & Ziegler AG Pentixa...
Constructive Bio Secures $58min Series A Financing (2024-09-24)
> Financing led by Ahren, OMX Ventures and Paladin Capital Group represents one of the largest UK biotech Series A rounds in recent years > Paladin Capital, Fine Structure Ventures, +ND Capital and Abcam-founder Jonathan Milner join as new investors > Sir Gre...
Launch of Aptadir Therapeutics to Develop RNA Inhibitors (2024-09-24)
> A novel approach for intractable cancers and genetic conditions > Science originates from 3 top international institutions – the Beth Israel Deaconess Medical Center of the Harvard Medical School, the Italian Research National Council (CNR) and the Cancer Sc...
Lift BioSciences Raises £10m in First Close of Series A (2024-09-24)
> Proceeds will be used to advance the Company’s IMANs into clinical trials > Raise underpins strong pre-clinical data demonstrating dual mechanism of action of LIfT’s IMANS LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech ...
Generate:Biomedicines & Novartis: Multi-target Collaboration (2024-09-24)
Potential total transaction valued at more than $1 billion with $65 million in total upfront consideration Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutic...
Altaris to Acquire Minaris Regenerative from Resonac Corp (2024-09-24)
Resonac Corporation (President: Hidehito Takahashi, hereinafter called “REC”), announces that it has entered into a definitive share purchase agreement (hereinafter called “this deal”) to transfer all of the issued shares in Minaris Regenerative Medicine, L...

» Show all News!

Life-Sciences-Europe.com is your doorway to the European life sciences!

[LSE] provides free, up-to-date and structured access to

– News
– Products
– Persons
– Organisations
– Financings
– Collaborations

in Europe and Israel.

Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSE] is 100% Made in Germany!

» Start here with the latest News!

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]